Show Hide image

MEDCAC panel reviews Dendreon Provenge impact

Review looks at treatment on health outcomes of patients with advanced prostate cancer.

The Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) has reviewed the impact of labelled and unlabeled use of Dendreon's Provenge (sipuleucel-T) treatment on health outcomes of patients with advanced prostate cancer.

The panel was convened as a part of the National Coverage Analysis (NCA) that was initiated by the Centres for Medicare and Medicaid Services (CMS).

Dendreon claimed that Provenge is the first in a new therapeutic class known as autologous cellular immunotherapies and is indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.

Dendreon president and CEO Mitchell Gold said that Provenge is an important new treatment for patients with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer.

"We look forward to working closely with CMS throughout the NCA process to ensure patients with advanced prostate cancer have access to Provenge," Gold said.

According to CMS, a draft guidance memo will be issued by 30 March 2011, and the expected NCA completion date is 30 June 2011.

Dendreon is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialisation and manufacturing of novel therapeutics.